Clinical trials: Stage I Gastric Cancer
Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
The goal of this clinical trial is to learn the efficaty and safety of BC001 in combination with Sintilimab and XELOX in treating patients with advanced or metastatic GC/GEJ.
- Trial name
- NCT06773312
- Testing
- BC001+Sintilimab+XELOX
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Malignant Ascites Caused by Advanced Solid Tumors
A Clinical Study of GK02 in Malignant Ascites
A single-arm, single-center, open-label clinical study comprising three cohorts, evaluating the safety, preliminary efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) characteristics of autologous tumor-reactive T cells…
- Trial name
- NCT07378436
- Testing
- GK02
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Geekgene Technology Co., LTD
Advanced Solid Tumors
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known…
- Trial name
- NCT07360314
- Testing
- M7437
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 138 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Advanced HER2-positive Breast Cancer or Gastric Cancer
Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer
This is a multicenter, open-label, dose escalation, phase I study to estimate the Maximum Tolerated Dose (MTD) or a lower Recommended Dose for Expansion (RDE) of LJM716 in combination with trastuzumab in patients with Human…
- Trial name
- NCT01602406
- Testing
- LJM716, Trastuzumab
- Where
- 11 sites in United States, Belgium and 7 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
This study will assess the safety and efficacy of INC280 in patients with solid tumors that are refractory to current treatment or for which there is not a current standard of care and whose tumors have dysregulation of the c-MET…
- Trial name
- NCT01324479
- Testing
- INC280
- Where
- 47 sites in United States, Australia and 13 more
- Volunteers
- 131 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer
A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors
The purpose of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokinetics (PK) of [68Ga]Ga-DWJ155, also known as FKL480, in patients ≥ 18 years of age with advanced gastroesophageal…
- Conditions
- Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer, Triple-negative Breast Cancer, Advanced Non-small Cell Lung Cancer
- Trial name
- NCT07801508
- Testing
- [68Ga]Ga-DWJ155
- Where
- 2 sites in Australia, Japan
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
This is a first-in-human (FIH), open-label, multi-site study which will evaluate the safety, efficacy, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid…
- Trial name
- NCT06750185
- Testing
- BNT317 DL1, BNT317 DL2, BNT317 DL3
- Where
- 11 sites in United States, Australia
- Volunteers
- 248 people
- Sponsor
- BioNTech SE
Advanced or Metastatic Solid Tumors
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are…
- Trial name
- NCT06781983
- Testing
- IPH4502
- Where
- 7 sites in United States, France
- Volunteers
- 145 people
- Sponsor
- Innate Pharma
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Cancer, Solid Tumor
ACTolog in Patients With Solid Cancers
The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.
- Trial name
- ACTolog (NCT02876510)
- Testing
- Fludarabine, Cyclophosphamide, IMA101 product
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Immatics US, Inc.
Breast Neoplasms, Peritoneal Neoplasms
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy
Monoclonal antibodies can transport and deliver radioactive elements capable of releasing sufficient amounts of energy to destroy tumor cells.
- Conditions
- Breast Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT01384253
- Testing
- ²¹²Pb-TCMC-Trastuzumab, trastuzumab
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Orano Med LLC
Gastric Cancer
Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer
The purpose of the phase 1 portion of the study is to determine the safe dose of S-1 and cisplatin that can be administered in gastric cancer patients.
- Trial name
- NCT00072787
- Testing
- S-1, cisplatin
- Where
- 11 sites in United States
- Volunteers
- 41 people
- Sponsor
- Taiho Oncology, Inc.
Solid Tumor, Metastatic Ovary Cancer
A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety and tolerability of TJ037130 in participants with advanced or metastatic solid tumors, and to determine the Potential Optimal Biological Dose (POBD) of TJ037130 for…
- Conditions
- Solid Tumor, Metastatic Ovary Cancer, Metastatic Gastric Cancer, Metastatic Endometrial Carcinoma
- Trial name
- NCT07715747
- Testing
- TJ037130
- Where
- China
- Volunteers
- 128 people
- Sponsor
- TJ Biopharma Co., Ltd.
Neoplasms
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
The purpose of this study Part A is to determine the safety, tolerability and the pharmacokinetics of BAY1143572 in subjects with advanced malignancies, which are either refractory to or ineligible for treatment with standard…
- Trial name
- NCT01938638
- Testing
- BAY1143572
- Where
- 12 sites in United States, Singapore and 2 more
- Volunteers
- 80 people
- Sponsor
- Bayer
Gastric Carcinoma
Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma
The purpose of this study is to investigate the maximum tolerated dose and pharmacokinetics of liposomal paclitaxel with/without capecitabine in Chinese cancer patients with advanced gastric carcinoma.
- Trial name
- NCT00639522
- Testing
- Liposomal paclitaxel and capecitabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Nanjing Sike Pharmaceutical Co., Ltd.
Gastric Cancer
A Study of E7070 in Patients With Gastric Cancer
Phase I study: To investigate primary objective (maximal tolerated dose and dose-limiting toxicity) and secondary objectives (pharmacokinetics, safety, estimation of a recommended dose, and anti-tumor effect by evaluable case) of…
- Trial name
- NCT00165594
- Testing
- E7070
- Where
- 5 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Eisai Co., Ltd.
Pathologic Stage I Gastric Cancer AJCC v8, Colorectal Cancer
Clinical Trial to Evaluate the Efficacy and Safety of a Thoracic and Abdominal Endoscopic Surgical System
Evaluation of the efficacy and safety of thoracic and abdominal endoscopic surgical systems manufactured by Shenzhen Cornerstone Robotics Technology Co., Ltd. for use in general, gynaecological and thoracic surgical procedures.
- Conditions
- Pathologic Stage I Gastric Cancer AJCC v8, Colorectal Cancer, Esophageal Cancer, Hepatectomy
- Trial name
- NCT06587152
- Testing
- Robot-assisted surgery
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Cornerstone Robotics
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Gastric Cancer, Gastro-esophageal Junction Cancer
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with…
- Conditions
- Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT06005493
- Testing
- AZD5863, AZD2936
- Where
- 25 sites in United States, China and 6 more
- Volunteers
- 392 people
- Sponsor
- AstraZeneca
Locally Advanced Solid Tumor, Metastatic Cancer
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer
- Trial name
- NCT04319757
- Testing
- ACE1702, Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 12 people
- Sponsor
- Acepodia Biotech, Inc.